期刊文献+

曲美他嗪对PCI患者的心肌保护作用

Cardioprotective Effect of Trimetazidine to PCI Patients
下载PDF
导出
摘要 目的探讨曲美他嗪对经皮冠状动脉介入治疗(PCI)患者的心肌保护作用。方法47例因急性心肌梗死(AMI)而行急诊PCI的患者随机分为曲美他嗪组(A组)和对照组(B组),A组在常规治疗的基础上于急诊PCI前后给予曲美他嗪口服,B组不用曲美他嗪。比较两组患者间血肌钙蛋白I(cTnI)、肌酸激酶同工酶(CK-MB)峰值浓度、CK-MB恢复正常的时间、再灌注心律失常及2W后的左室功能。结果(1)A组和B组患者分别为24例和23例,两组临床基线资料无统计学差异。(2)A组cTnI峰值浓度和CK-MB峰值浓度分别为(1.23±0.98)ng/mL和(114±67)U/L,显著低于B组的(2.36±1.28)ng/mL和(159±72)U/L(P<0.05);A组CK-MB峰值时间和恢复正常的时间均显著短于B组(P<0.05或0.01)。(3)A组33%(8例)发生再灌注心律失常,显著低于B组的65%(15例)(P<0.05)。(4)2W后超声心动图检测的左室射血分数A组为(58±10)%,显著高于B组的(51±10)%(P<0.05)。结论对急诊PCI的急性心肌梗死患者,曲美他嗪可能缩小梗死面积,减轻再灌注损伤,保护心脏功能。 Objective To investigate the cardioprotective effect to emergency PCI patients.Methods:47 patients with acute myocardial infarction(AMI) who admitted for emergency PCI were randomly divided into two groups:Group A Timmetazidine Group and Group B comparison Group.Patients in Group A tock timmetazidine orally before and after thrombolysis,while those in Group B received conventional therapy.The differences of cTnI、peak consistency of CK-MB、normalization time of CK-MB、repedusion arrhythmias and left ventricular function two weeks later were compared between this two groups.Results:(1)There were 24 patients in Group A and 23 in Group B,no significant differences in baseline characteristics between this two groups.(2) Peak consistency of cTnI and CK-MB of Group A are(1.23±0.98) ng/mL and(114±67) U/L respectively,significantly lower(2.36±1.28) ng/mL and(159±72)U/L(P<0.05) than that in Group B;Peak time of CK-MB and normalization time in Group A were shorter than that in Group B(P<0.05 or 0.01).(3) 33% of patients in Group A(8 patients) suffered reperfussion arrhythmias while 65%(15 patients) in Group B(P<0.05),lower than that in Group A.(4) Examination of supersonic electrocardiogram showed that blood shooting in the left ventricle of the heart was(58±10)% in Group A,higher than that in Group B(51±10)%(P<0.05).Conclusion:For those emergency PCI patients,timmetazidine administration may reduce infarct size and reperfusion damage,protect function of the heart.
出处 《延安大学学报(医学科学版)》 2008年第2期19-20,22,共3页 Journal of Yan'an University:Medical Science Edition
关键词 曲美他嗪 急性 心肌 急诊 Timmetazidine Myocardial infarction emergency PCI
  • 相关文献

参考文献8

  • 1中国曲美他嗪多中心临床研究协作组,胡大一,赵秀丽.曲美他嗪对稳定性劳力型心绞痛的疗效观察[J].中华心血管病杂志,2000,28(5):339-341. 被引量:173
  • 2麦炜颐,曾群英,王礼春,何清,陈国伟,冯冲.曲美他嗪改善缺血性心肌病患者心功能的临床研究[J].临床心血管病杂志,2000,16(8):382-383. 被引量:18
  • 3Kantor PF,Lucien A,Kozak R,et al.The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondral long chain3 ketoacyl coenzyme a thiolase[].Circulation Research.2000
  • 4Steg P G,Grollier G,Gallay P,et al.A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction[].International Journal of Cardiology.2001
  • 5Lopaschuk G D,Kozak R.Trimetazidine inhibits fatty acid oxidation in the heart[].Journal of Molecular and Cellular Cardiology.1998
  • 6Kantor PF,Lucien A,Kozak R,et al.The antianginal drugtrimetazidine shifts cardiac energy metabolism from fattyacid oxidation to glucose oxidation by inhibiting mitochon-drial long-chain[]..
  • 7FUCH S S,KORNOW SKI R,M EH REN R,etal.Prognostic vale of cardiac troponin-I levels following catheter-based coronary intervention[].The American Journal of Cardiology.2000
  • 8El Banani H,Bernard M,Baetz D,et al.Changes in intracellular sodium and pH during ischemiareperfusion are attenuated by trimetazidine.Comparison between low-and zero-flow ischaemia[].Cardiovascular Research.2000

二级参考文献14

  • 11,Opie L H.Proof that glucose-insalin potassium provides metabolic protection of ischemia myocardium?Lancet,1999,353:768~769
  • 22,Manchanda S C,Krishnaswami S.Combination treatment with trimetazidine and diltiazem in stable angina pectoris.Heart,1997,78:353~357
  • 33,Detry J M,Leclercq P J.Trimetazidine European Multicenter study versus propranold in stable angina pectoris:contribution of Holter electrocardiographic ambulatory mornitoring.Am J Cardiol,1995,76:8B~11B
  • 44,Nomenclature and criteria for diagnosis of ischemic heart disease.Report of the joint International and Federation of Cardiology/World Health Organization task force on Standarization of clinical nomendature.Circulation,1979,59:607~609
  • 55,Lee D C,Johnson R A,Bingham J B,et al.Heart failure in out patients:A randomized trial of digoxin versus Placebo.N Engl J Med,1982,306:699~705
  • 66,Schafers M,Matheja P,Hasfeld M,et al.The clinical impact of thallium-201 reinjection for the detection of myocardial hibernation.Eur J Nucl Med,1996,23:407~413
  • 77,Lopaschuk G D.Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism.Presses Med,1998,27:2100~2104
  • 88,Opie L H.The Heart 2nd ed.New York:Raven Press,1991:211~212
  • 99,El-Bancuni H,Bernard M,Cozzone P,et al.Ionic and metabolic imbalance as potential factors of ischemia reperfusion injury.Am J Cardiol,1998,82:25K~29K
  • 1010,Williams F M,Tanda K,Kus M,et al.Trimetazidire inhibits neutrophil accummulation after myocardial ischemia and reperfusion in rabbits.J Cardiovasc Pharmacd,1993,22:828~833

共引文献178

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部